Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment

Publication Type:

Conference Proceedings

Source:

The Liver Meeting, Boston, MA (2017)
Top